Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,463
Recruiting: 820
Ph III recruiting: 96
Growth YoY: +6.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 151–200 of 301 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06253494	Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer	recruiting	Phase 1 / Phase 2	60	National Cancer Institute (NCI)NIH	1	Apr 9, 2026	clinicaltrials
NCT07514494	Intensification Treatment of Ovarian Cancer by PIPAC(PrimPIPAC)	recruiting	Phase 2	160	Moscow Regional Oncological DispensaryOTHER_GOV	1